This node covers the research infrastructure that turns aging-linked disease burden into funded laboratory work, clinical trials, biological data, and discovery software before a drug, diagnostic, or care pathway reaches patients. The stack includes lab instruments, reagents, recurring consumables, sequencing systems, spatial and single-cell workflows, clinical-research services, real-world evidence data, and computational chemistry software. It sits in pharma, biotech, academic, diagnostic, CRO, and regulated lab workflows, where customer budgets become instrument placements, consumable pull-through, service revenue, backlog conversion, annual contract value, and cash flow. TMO and DHR remain the broadest paid-infrastructure anchors; A, ILMN, WAT, QGEN, and TXG give focused lab and omics exposure; IQV and MEDP show whether sponsor funding is becoming clinical-development work; SDGR is the direct AI-discovery software slot because ACV and enterprise adoption are measurable.
What the stack is: life-science tools are the instruments, consumables, assays, lab services, software, and clinical-development services used before therapies, diagnostics, and evidence programs become commercial products.
What it does: the stack prepares biological samples, runs analytical chemistry, sequences DNA and RNA, measures single-cell and spatial biology, supports regulated quality-control labs, manages clinical studies, produces real-world data, and screens molecules with computational tools.
Main operating pieces: mass spectrometers, chromatography systems, sequencers, flow cytometers, pathology and diagnostics platforms, reagents, cartridges, sample-prep kits, lab automation, CRO project teams, patient and claims data, computational chemistry software, and enterprise hosted workflows.
Where it sits: instruments and consumables sit inside pharma, biotech, academic, diagnostic, industrial, and regulated labs; CRO work sits in sponsor trial operations; real-world data sits in evidence and commercial analytics; computational discovery software sits in medicinal chemistry and model-driven research workflows.
How the parent theme uses it: aging demand increases chronic-disease, oncology, cardiometabolic, diagnostic, and evidence-generation workloads. The node is investable only when that activity is funded by customers and shows up in revenue, recurring mix, backlog, ACV, margin, free cash flow, or lower cash burn.
Terms used later: installed base means instruments already placed with customers; consumable pull-through means repeat reagent or cartridge revenue from that installed base; book-to-bill compares new CRO awards with current revenue; backlog conversion is contracted work becoming revenue; ACV means annual contract value for recurring software or hosted workflows.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, setup labels, confirmation triggers, invalidation levels, and chart provenance. Durable company research, raw source registries, and security thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Paid research infrastructureRecurring lab use and backlog conversion matter more than AI headlines.
The best node evidence is still reported revenue, consumable use, CRO awards, software ACV, and cash conversion across scaled tools, omics workflows, and clinical-development services.
Best proofTMO, DHR, and A carry the broadest workflow evidence.
They touch pharma, biotech, diagnostics, academic, industrial, and regulated labs.
Conversion gateOmics and CRO exposure must repeat through use, awards, and cash.
Watch ILMN consumables, QGEN stabilization, TXG Atera, IQV backlog, and MEDP awards.
Main constraintFunding, China, tariffs, instrument cycles, and platform burn can absorb the benefit.
AI discovery needs paid adoption, margin, partner economics, and lower dilution risk.
Demand sourceAging disease workload
Customer paysPharma, biotech, lab, CRO
Economic proofRevenue, mix, backlog, ACV
Live watchFunding, China, cash
Aging demand raises the amount of chronic-disease research, oncology and cardiometabolic development, diagnostic testing, clinical trial work, and translational data required before new treatments reach patients. This node captures the paid infrastructure behind that work: instruments placed in labs, consumables used on installed systems, sequencing and spatial biology data generation, CRO backlog conversion, real-world evidence, and computational chemistry software. The measured proof is orders, consumable pull-through, book-to-bill, backlog conversion, ACV, cash conversion, and customer funding commentary.
The strongest current evidence is still in scaled tools and recurring workflow revenue. TMO, DHR, and A give broad read-through across pharma, biotech, academic, diagnostics, and regulated labs. ILMN, QGEN, and TXG add omics exposure where recurring consumables matter more than one-time instrument sales. WAT gives a regulated analytical workflow route after the BD asset deal. IQV and MEDP monitor whether trial starts and sponsor funding are converting into backlog and cash. SDGR keeps one direct AI-discovery software slot because ACV and enterprise adoption are measurable.
AI headlines require paid adoption, recurring revenue, margin, and cash proof. NIH and academic funding, small-biotech financing, pharma budget timing, China demand, tariffs, instrument replacement cycles, CRO cancellations, acquisition debt, and platform cash burn can all absorb the benefit before shareholders see it. ICLR and RXRX were moved out of the core basket after the tournament merge: ICLR has control and backlog-comparability issues, while RXRX is a high-purity AI-biology platform whose economics still depend on clinical and partner proof. The static setup thresholds were built before the API-resolved 2026-06-12 weekly bar, so treat them as stale watch levels until regenerated.
Right-rail charts use weekly bars aggregated from discovery daily_ohlc through 2026-06-12. The static setup thresholds were built on the prior package and are stale as current trading evidence; refresh discovery, setup levels, and source trails together before using them for live decisions. Fundamental claims route to the Health Care sector lane, AI Biology Platform Validation theme, linked security lanes, sibling AI-biology node pages, and official company releases listed in the Source Trail.
Basket
The basket is hand-curated from the existing node sidecar, parent theme, local knowledge lanes, and read-only discovery coverage. Ranking uses paid node economics and source-backed exposure first, then recurring mix, cash quality, customer-funding sensitivity, AI-discovery proof, and technical timing. TMO ranks first because it has the broadest lab, services, diagnostics, and clinical-research footprint. DHR and A keep scaled recurring tools exposure near the top. ILMN, WAT, QGEN, and TXG are narrower omics or regulated-lab routes. IQV and MEDP monitor clinical-development funding. SDGR is included because software ACV and hosted adoption are measurable.
Local coverage maps Life Sciences Solutions, Analytical Instruments, Laboratory Products and Biopharma Services, and Specialty Diagnostics as the main routes. LPBS is the largest revenue segment and LSS carries a larger share of segment income; Clario adds clinical-trial endpoint data but also leverage and integration proof.
Latest qtr revenue
Q1 2026 revenue was $11.01B, up 6% reported and 1% organic, from the Thermo Fisher Q1 2026 release. The next proof is organic growth moving toward the 3%-4% FY2026 guide while Clario contributes without weakening cash conversion.
Recurring bioprocessing, diagnostics, life-science tools, and lab automation exposure.
Market cap$127.47B
Next earningsJul 21, 2026
Latest qtr revenue$5.95B
Role in stack
Danaher sells bioprocessing, diagnostics, molecular tools, lab automation, imaging, and life-science workflow products through Cytiva/Pall, Beckman, Leica, SCIEX, IDT, and related platforms. The node mechanism is recurring consumables, service attachment, diagnostics workflow volume, core growth, margin, and free cash flow.
Revenue mix
Biotechnology, Life Sciences, and Diagnostics all matter to this node, with recurring consumables and service exposure more important than one-time instrument sales. The Masimo transaction adds diagnostics scale but raises financing and integration checks.
Latest qtr revenue
Q1 2026 revenue was $5.95B from the Danaher Q1 2026 release, with core growth positive and Q1 free cash flow about $1.1B in local coverage. The rank depends on core growth moving toward the FY2026 guide and Biotechnology strength broadening.
Focused analytical-instrument, CrossLab service, pathology, and lab-workflow route.
Market cap$36.67B
Next earningsNot confirmed
Latest qtr revenue$1.835B
Role in stack
Agilent sells analytical instruments, lab automation, pathology, companion diagnostics, advanced-therapeutics tools, CrossLab services, and regulated workflow software. Customer budgets convert through instrument demand, service attach, CrossLab margins, Biocare integration, and cash conversion.
Revenue mix
Local coverage highlights CrossLab as the recurring-quality anchor and maps instruments, diagnostics, applied markets, and service workflows. It is the best focused lab-workflow name in the basket, but it still needs cash conversion after H1 softness.
Latest qtr revenue
Fiscal Q2 2026 revenue was $1.835B, up 10.0% reported and 6.3% core, from the Agilent Q2 FY2026 release. StockAnalysis showed the last earnings date as May 27, 2026; no credible future date was confirmed during the June 13 check.
Scaled sequencing route where installed systems need recurring consumable utilization.
Market cap$24.35B
Next earningsJul 30, 2026
Latest qtr revenue$1.091B
Role in stack
Illumina sells sequencing instruments, consumables, arrays, services, and data workflows into research, clinical, translational, and pharma customers. The node mechanism is instrument placements becoming sequencing runs, consumable revenue, multiomics data, margin, and free cash flow.
Revenue mix
Consumables dominate the Q1 mix, making utilization more important than instrument shipments alone. NovaSeq X placements, Greater China, SomaLogic integration, buybacks, and debt timing decide whether the recovery is durable.
Latest qtr revenue
Q1 2026 revenue was $1.091B from the Illumina Q1 2026 release. Consumables were $797M, or about 73% of revenue; instruments were $120M; service and other revenue was $174M.
Regulated analytical workflow route with a large BD integration and cash-conversion gate.
Market cap$34.91B
Next earningsNot confirmed
Latest qtr revenue$1.267B
Role in stack
Waters sells LC/MS, chromatography, chemistry, bioanalysis, regulated QA/QC, lab informatics, and the acquired BD Biosciences and Advanced Diagnostics assets. Customer activity converts through organic growth, acquired revenue retention, segment margin, integration-cost runoff, debt movement, and free cash flow.
Revenue mix
Local coverage splits Q1 revenue across Analytical and Materials Sciences, Biosciences, and Advanced Diagnostics. The legacy analytical franchise remains the quality anchor; acquired BD revenue adds scale but also leverage, disclosure, and adjusted-to-GAAP quality checks.
Latest qtr revenue
Q1 2026 revenue was $1.267B from the Waters Q1 2026 release. Organic constant-currency revenue grew 11.9%, and acquired BD revenue was about $520M. StockAnalysis showed the last earnings date as May 5, 2026; no credible future date was confirmed during the June 13 check.
Clinical-development and real-world-data bridge from disease burden to evidence work.
Market cap$30.29B
Next earningsJul 21, 2026
Latest qtr revenue$4.151B
Role in stack
IQVIA sells clinical-development services, real-world evidence, commercial analytics, patient data, and healthcare AI workflows to biopharma sponsors. Aging demand converts when trial starts, analytics demand, and sponsor budgets become R&DS backlog, Commercial Solutions revenue, cash flow, and lower leverage.
Revenue mix
Q1 2026 revenue split between R&D Solutions and Commercial Solutions. The R&DS backlog and expected 12-month conversion are the node proof because they show contracted work moving toward revenue.
Latest qtr revenue
Q1 2026 revenue was $4.151B from the IQVIA Q1 2026 release: R&D Solutions was $2.397B and Commercial Solutions was $1.754B. R&DS backlog was $34.2B, with $8.9B expected to convert over the next 12 months.
Focused CRO with strong current revenue and cash, but weaker new-award proof.
Market cap$13.35B
Next earningsJul 20, 2026
Latest qtr revenue$706.6M
Role in stack
Medpace provides full-service clinical trial work for biotech, pharma, and medical-device sponsors. The conversion mechanism is awards, study starts, backlog, therapeutic-area execution, EBITDA margin, operating cash flow, and a net-cash balance sheet.
Revenue mix
MEDP is narrower than IQV but cleaner operationally. The local lane flags Q1 net book-to-bill of 0.88x and elevated cancellations, so revenue strength must be compared with new awards and backlog quality.
Latest qtr revenue
Q1 2026 revenue was $706.6M from the Medpace Q1 2026 release, up 26.5%. EBITDA was $149.4M, a 21.1% margin; cash was $652.7M and debt was zero in the local lane.
Computational chemistry software slot where ACV and hosted adoption are observable.
Market cap$1.08B
Next earningsNot confirmed
Latest qtr revenue$58.6M
Role in stack
Schrodinger sells computational chemistry software, hosted enterprise workflows, Bunsen, drug-discovery collaborations, and internal discovery programs. The node mechanism is ACV growth, renewals, hosted adoption, software gross margin, partner economics, cash runway, and lower burn.
Revenue mix
Software revenue is the reason SDGR belongs in this healthcare-aging node rather than only the platform-biotech watch list. Drug-discovery revenue and internal pipeline value are useful, but they are lumpier and should not carry the rank without software proof.
Latest qtr revenue
Q1 2026 revenue was $58.6M from the Schrodinger Q1 2026 release. Software revenue was $35.6M, drug-discovery revenue was $22.9M, ACV was $28.4M, up 12%, and cash plus restricted cash and securities was about $406M. StockAnalysis showed the last earnings date as May 5, 2026; no credible future date was confirmed during the June 13 check.
Recurring molecular workflow route with guide-reset and cash-conversion checks.
Market cap$7.66B
Next earningsNot confirmed
Latest qtr revenue$492.3M
Role in stack
QIAGEN sells molecular sample prep, assays, PCR/dPCR, QuantiFERON, syndromic diagnostics, NGS workflows, Parse single-cell exposure, and bioinformatics. Theme pressure converts through consumables, molecular testing volume, U.S. life-science demand, margin, and free cash flow.
Revenue mix
FY2025 sales were $2.09B and consumables and related revenue were $1.876B, about 90% of sales. That recurring mix earns a core slot, but Q1 weakness and FY2026 guide reset make this a recovery proof case.
Latest qtr revenue
Q1 2026 sales were $492.3M from the QIAGEN Q1 2026 release, down 1% CER, and FY2026 sales guidance reset to 1%-2% CER growth. StockAnalysis showed the last earnings date as May 6, 2026; no credible future date was confirmed during the June 13 check.
Single-cell and spatial biology route where consumables are real but Atera proof is ahead.
Market cap$3.66B
Next earningsNot confirmed
Latest qtr revenue$150.8M
Role in stack
10x sells single-cell and spatial biology instruments, consumables, software, and services to research and translational labs. The mechanism is installed systems and Atera launches creating reaction volume, consumable pull-through, Spatial growth, gross margin, and normalized operating cash flow.
Revenue mix
Consumables are the economic core, while instruments seed future consumables demand. Atera demand remains qualitative until shipments, backlog, ASP, capacity, cancellation risk, and consumable pull-through are disclosed.
Latest qtr revenue
Q1 2026 revenue was $150.8M from the 10x Genomics Q1 2026 release and local lane. Consumables were $129.8M, about 86% of revenue; instruments were $11.3M; services were $8.8M; Spatial consumables grew 31%. StockAnalysis showed the last earnings date as May 7, 2026; no credible future date was confirmed during the June 13 check.
Market caps and earnings-date checks used StockAnalysis quote pages accessed 2026-06-13. TMO, DHR, ILMN, IQV, and MEDP had future dates visible; A, WAT, SDGR, QGEN, and TXG only showed already-reported May 2026 dates in the accessible static checks, so their next earnings fields are marked Not confirmed. Watch list: BRKR, TECH, CERT, CRL, ICLR, RXRX, ABCL, TWST, and PACB. BRKR and TECH are first tools rotate-ins; CERT is the first second-software rotate-in; RXRX and ABCL stay AI-biology watch names.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesis
Paid research workload
What confirms
R&D budgets, lab orders, consumables, CRO awards, backlog conversion, software ACV, and cash conversion improve across more than one basket sleeve.
What weakens or invalidates
AI, omics, or lab-automation announcements do not show up in paid adoption, recurring revenue, margin, backlog, ACV, or free cash flow.
Watch next
Quarterly order commentary
NIH and academic funding
Biotech financing
ACV and FCF
02Economics mechanism
Revenue to cash
What confirms
TMO, DHR, A, and WAT show organic growth, service attach, consumable pull-through, acquisition integration progress, stable margins, and free cash flow.
What weakens or invalidates
Instrument replacement cycles stall, China weakens, academic or government demand stays slow, tariffs pressure margins, or M&A debt absorbs cash.
Watch next
TMO organic guide and Clario
DHR Biotechnology and Masimo
A CrossLab and Biocare
WAT BD cash flow
03Customer and utilization
Omics and molecular workflows
What confirms
ILMN, QGEN, and TXG turn installed systems into repeat consumables, clinical or translational utilization, product/services revenue, gross margin, and cash.
What weakens or invalidates
Consumables slow after placements, instruments stay weak, China or U.S. life-science funding delays persist, or Atera, Parse, and SomaLogic proof slips.
Watch next
NovaSeq X utilization
QGEN QuantiFERON
TXG Atera shipments
Spatial consumables
04Clinical translation
Trial starts and backlog
What confirms
IQV and MEDP report book-to-bill at or above 1.0x, lower cancellations, backlog conversion, RFP activity, margin stability, and operating cash flow.
What weakens or invalidates
Sponsor cancellations rise, biotech funding tightens, backlog growth slows, or trial starts shift later without pricing, margin, and cash support.
Watch next
IQV R&DS backlog
IQV leverage
MEDP awards
MEDP 2027 backlog bridge
05Funding and policy
Customer budget gate
What confirms
NIH awards catch up, academic and small-biotech budgets stabilize, pharma pipelines fund external work, tariff pressure is absorbed, and CRO awards recover.
What weakens or invalidates
Grant delays, selective credit, pharma reprioritization, China restrictions, or reimbursement pressure cause customers to defer instruments, services, trials, or data subscriptions.
Watch next
AAMC and NIH checks
Health Care sector lane
CRO award commentary
Tool-order language
06Operating and supply constraint
Execution costs
What confirms
Segment margins hold while acquisitions integrate, service capacity expands, instrument supply normalizes, and software hosted gross margin improves.
What weakens or invalidates
Integration costs, debt service, China exposure, tariffs, inventory, service labor, platform hosting costs, or customer-support costs consume revenue growth before cash conversion.
Watch next
WAT and DHR integration
TMO leverage
SDGR hosted margin
TXG Atera launch costs
07Stale condition
Refresh trigger
What confirms
Discovery, source lanes, quarterly releases, earnings-date checks, market-cap checks, and report API chart assumptions remain current with no material new filing or event.
What weakens or invalidates
A new filing, earnings release, financing, FDA update, guidance change, acquisition update, or completed trading session changes the evidence base or setup labels.
10x Genomics Q1 2026 results and the linked TXG knowledge lane for Q1 revenue, consumable mix, and Atera shipment evidence. The official site returned a Cloudflare challenge during the 2026-06-13 direct fetch, so the local lane and clipped SEC/release evidence carry the revenue detail.
Market-cap metrics use StockAnalysis quote pages accessed 2026-06-13 for TMO, DHR, A, ILMN, WAT, IQV, MEDP, SDGR, QGEN, and TXG. Values are point-in-time quote-page fields and should be refreshed with market data.
Future earnings dates visible on the accessible StockAnalysis pages were TMO Jul 22, 2026; DHR Jul 21, 2026; ILMN Jul 30, 2026; IQV Jul 21, 2026; and MEDP Jul 20, 2026. The page treats these as calendar-source dates, not official company confirmations.
A, WAT, SDGR, QGEN, and TXG returned only already-reported May 2026 earnings dates in accessible static calendar checks. Their cards use Not confirmed rather than an inferred August 2026 estimate.
Right-rail chart metadata uses read-only discovery daily_ohlc rows through 2026-06-12 for TMO, DHR, A, ILMN, WAT, IQV, MEDP, SDGR, QGEN, and TXG.
Weekly packages use first open, maximum high, minimum low, final close, summed volume, 20-week EMA, and 100-week EMA. The selected-security chart rail expects /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest, uses a three-year visible horizon, and renders through the report API rather than embedded HTML payloads.
Review validation reached /api/securities/TMO/chart?frequency=weekly&window=3y&as_of=latest after loopback escalation. The route returned HTTP 200 with a normal JSON envelope, weekly rows, and resolved_as_of 2026-06-12.
Static setup thresholds in report.json predate the API-resolved 2026-06-12 weekly bar. Refresh DuckDB coverage, weekly levels, source trail, and sidecar metadata together before treating the setup labels as current trading evidence.
Subagent Tournament
Ten primary subagents ranked the basket through lenses including diversified tools, omics, AI-discovery software, lab automation, bioprocessing and consumables, aging-demand conversion, technical setup, source quality, valuation quality, and creative tails.
One merge/select subagent used a pairwise tournament and selected TMO, DHR, A, ILMN, WAT, IQV, MEDP, SDGR, QGEN, and TXG as the final core basket.
The merge moved ICLR and RXRX out of the parent core and into watch because ICLR has control and backlog reset risk, while RXRX is more appropriate for the dedicated AI-biology watch sleeve.
Known Gaps
TMO's local lane is slightly older than several June 7 refreshes, so the next update should refresh Clario, NVIDIA, leverage, short interest, and peer valuation together.
TXG and QGEN were promoted into core from the broader healthcare/AI-biology overlap. Their next rank depends on Q2 2026 evidence for Atera, QuantiFERON, U.S. life-science demand, cash conversion, and guide durability.
RXRX, ABCL, CERT, BRKR, TECH, TWST, and PACB remain useful bench names, but the page should not treat them as core until paid adoption, growth, margin, cash, and chart evidence improve relative to the current top 10.